Trametinib
- Generic Name
- Trametinib
- Brand Names
- Mekinist, Spexotras
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23FIN5O4
- CAS Number
- 871700-17-3
- Unique Ingredient Identifier
- 33E86K87QN
- Background
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...
- Indication
Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
It is used in combination with dabrafenib for the:
...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
- Associated Therapies
- -
Long-Term Analysis Shows Tafinlar Plus Mekinist Reduces Mortality Risk in Stage III Melanoma
12 months of adjuvant Tafinlar (dabrafenib) plus Mekinist (trametinib) improved relapse-free survival (RFS) and distant metastasis–free survival (DMFS) in resected stage III melanoma patients, with a 20% reduced risk of death overall and a 25% reduction among those with a BRAF V600E mutation, though overall survival (OS) benefit was not statistically significant.
FDA Approves MI Cancer Seek as Companion Diagnostic for Adult and Pediatric Patients
The FDA has approved MI Cancer Seek, a companion diagnostic test using whole exome and transcriptome sequencing to identify cancer patients eligible for targeted therapies, including pan-cancer and tumor-specific indications.
Caris Life Sciences Receives FDA Approval for MI Cancer Seek™ as a Companion
Caris Life Sciences announces FDA approval of MI Cancer Seek, the first simultaneous Whole Exome and Whole Transcriptome Sequencing-based assay with CDx indications for molecular profiling of solid tumors, available for adults and pediatric patients.
MI Cancer Seek Receives FDA Approval as Companion Diagnostic for Targeted Therapy
FDA approves MI Cancer Seek as companion diagnostic for cancer patients aged 1-22, offering comprehensive molecular profiling via whole-exome and whole-transcriptome sequencing. The diagnostic includes indications for breast, colorectal, melanoma, non-small cell lung, endometrial, and solid tumors, aiding in targeted therapy decisions.
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Erasca announces positive Phase 1b SEACRAFT-1 data for naporafenib plus trametinib in NRASm melanoma, supporting ongoing Phase 3 SEACRAFT-2 trial. SEACRAFT-2 aligns with US and European regulatory paths, with Stage 1 randomized data expected in 2025. The company also reports rapid progress in its RAS targeting franchise, with planned IND submissions on track.
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
Large drug-maker stocks surged, driven by FDA approvals and pipeline innovations. Eli Lilly, Roche, Novartis, and Pfizer are top picks for long-term gains. Eli Lilly's tirzepatide drugs and Novo Nordisk's semaglutide drugs are top sellers. Despite M&A scrutiny, activities remained strong. Large drug-makers offer robust revenue streams and profitability.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath